NFKB1 and breast cancer: However, the introduction of a MyD88 inhibitor disrupted the signal transduction of the TLR3-MyD88-NF-κB (p65)-IL6-Cyclin D1 pathway, leading to reduced breast cancer cell proliferation (37).